What's Going On With uniQure Stock Wednesday?

Benzinga_recent_news03-04 22:58

uniQure N.V. (NASDAQ:QURE) shares edged higher Wednesday after plunging in the previous session following an FDA setback related to the company’s investigational Huntington’s disease gene therapy. The...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616555977?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/04/FDA_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-04 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616555977","market":"hk","top_or_hot":-1,"title":"What's Going On With uniQure Stock Wednesday?","media":"Benzinga_recent_news","content":"<div>\n<p>uniQure N.V. (NASDAQ:QURE) shares edged higher Wednesday after plunging in the previous session following an FDA setback related to the company’s investigational Huntington’s disease gene therapy.\nThe...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51035933/whats-going-on-with-uniqure-stock-wednesday-2\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With uniQure Stock Wednesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With uniQure Stock Wednesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 22:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/03/51035933/whats-going-on-with-uniqure-stock-wednesday-2><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>uniQure N.V. (NASDAQ:QURE) shares edged higher Wednesday after plunging in the previous session following an FDA setback related to the company’s investigational Huntington’s disease gene therapy.\nThe...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51035933/whats-going-on-with-uniqure-stock-wednesday-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51035933/whats-going-on-with-uniqure-stock-wednesday-2","article_id":"2616555977","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/04/FDA_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51035933/whats-going-on-with-uniqure-stock-wednesday-2","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616555977","pubTimestamp":1772636280,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"QURE hits bearish territory after FDA trial news. With shares near 52-week lows, see the key support and resistance levels to watch.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4217":"自存仓储房地产信托","SMA":"Smartstop Self Storage REIT Inc","QURE":"uniQure N.V.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"周三uniQure股票发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMA":1,"QURE":1},"content_text":"uniQure N.V. (NASDAQ:QURE) shares edged higher Wednesday after plunging in the previous session following an FDA setback related to the company’s investigational Huntington’s disease gene therapy.\nThe sharp decline came after the U.S. Food and Drug Administration advised against using Phase 1/2 study data as the primary evidence for the marketing application of AMT-130, raising uncertainty around the therapy’s regulatory path.\nThe FDA on Monday strongly recommended that uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study to proceed with its application.\nuniQure plans to request a Type B meeting in the second quarter of 2026 for further discussions regarding the therapy’s development.\nThis setback comes as the company continues to advance its pipeline of proprietary gene therapies targeting severe diseases, including Huntington’s disease, refractory temporal lobe epilepsy, ALS, and Fabry disease.\nThe stock is currently trading 14.29% below its 20-day simple moving average (SMA) and 30.00% below its 100-day SMA, indicating a bearish trend. Shares have decreased significantly over the past 12 months and are currently positioned closer to their 52-week lows than highs.\nThe RSI is at 50.00, which is considered neutral territory. Meanwhile, MACD is at -0.10, below its signal line at 0.00, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $39.69. Recent analyst moves include:\nQURE Price Action: uniQure shares were up 1.50% at $9.16 at the time of publication on Wednesday. The stock is trading near its 52-week low of $7.76, according to Benzinga Pro data.\nPhoto by Tada Images via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616555977","isCrawlerRequest":true}